ResMed (RMD) 10-Q 30 Oct 13 2014 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Sep. 30, 2013	Oct. 24, 2013
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	30-Sep-13
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q1
Entity Registrant Name	RESMED INC
Entity Central Index Key	943819
Current Fiscal Year End Date	-24
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		142,081,434

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$976,574	$876,048
Accounts receivable, net of allowance for doubtful accounts of $12,311 and $9,912 at September 30, 2013 and June 30, 2013, respectively	282,425	318,349
Inventories (note 4)	175,355	145,847
Deferred income taxes	43,324	38,552
Income taxes receivable	2,988	8,910
Prepaid expenses and other current assets	77,268	61,143
Total current assets	1,557,934	1,448,849
Non-current assets:
Property, plant and equipment, net (note 5)	416,745	411,433
Goodwill and other intangible assets, net (note 7)	332,118	324,468
Deferred income taxes	22,618	20,053
Other assets	5,220	5,918
Total non-current assets	776,701	761,872
Total assets	2,334,635	2,210,721
Current liabilities:
Accounts payable	57,125	60,688
Accrued expenses	135,847	137,674
Deferred revenue	43,908	44,953
Income taxes payable	13,453	30,090
Deferred income taxes	731	627
Current portion of long-term debt (note 8)	360,018	300,017
Total current liabilities	611,082	574,049
Non-current liabilities:
Deferred income taxes	14,539	9,895
Deferred revenue	12,125	11,928
Long-term debt (note 8)	790	769
Income taxes payable	3,564	3,564
Total non-current liabilities	31,018	26,156
Total liabilities	642,100	600,205
Commitments and contingencies (notes 13)
Stockholders' equity: (note 11)
Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued
Common stock, $0.004 par value, 350,000,000 shares authorized; 174,428,613 issued and 141,970,905 outstanding at September 30, 2013 and 174,038,766 issued and 142,012,753 outstanding at June 30, 2013	568	568
Additional paid-in capital	1,044,489	1,025,064
Retained earnings	1,622,093	1,576,641
Treasury stock, at cost, 32,457,708 shares at September 30, 2013, and 32,026,013 shares at June 30, 2013	-1,104,906	-1,083,845
Accumulated other comprehensive income	130,291	92,088
Total stockholders' equity	1,692,535	1,610,516
Total liabilities and stockholders' equity	$2,334,635	$2,210,721

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Jun. 30, 2013
In Thousands, except Share data, unless otherwise specified
Consolidated Balance Sheets [Abstract]
Accounts receivable, allowance for doubtful accounts	$12,311	$9,912
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	350,000,000	350,000,000
Common stock, shares issued	174,428,613	174,038,766
Common stock, shares outstanding	141,970,905	142,012,753
Treasury stock, shares held	32,457,708	32,026,013

Consolidated_Statements_Of_Inc

Consolidated Statements Of Income (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Consolidated Statements Of Income [Abstract]
Net revenue	$357,662	$339,731
Cost of sales	129,680	131,083
Gross profit	227,982	208,648
Operating expenses:
Selling, general and administrative	101,323	98,303
Research and development	27,363	27,220
Amortization of acquired intangible assets	2,412	2,636
Total operating expenses	131,098	128,159
Income from operations	96,884	80,489
Other income, net:
Interest income	6,414	8,471
Other, net	-1,228	1,941
Total other income, net	5,186	10,412
Income before income taxes	102,070	90,901
Income taxes	21,140	19,636
Net income	$80,930	$71,265
Basic earnings per share	$0.57	$0.50
Diluted earnings per share (note 3)	$0.56	$0.49
Dividend declared per share	$0.25	$0.17
Basic shares outstanding	142,005	142,651
Diluted shares outstanding	145,456	146,055

Consolidated_Statements_Of_Com

Consolidated Statements Of Comprehensive Income (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Consolidated Statements Of Comprehensive Income [Abstract]
Net income	$80,930	$71,265
Other comprehensive income:
Foreign currency translation gain adjustments	38,203	18,857
Comprehensive income	$119,133	$90,122

Consolidated_Statements_Of_Cas

Consolidated Statements Of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:
Net income	$80,930	$71,265
Adjustment to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	17,870	18,650
Stock-based compensation costs	10,816	7,921
Foreign currency revaluation	-1,653	-1,741
Excess tax benefit from stock-based compensation arrangements	-2,241	-3,760
Changes in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable, net	40,268	18,397
Inventories, net	-26,847	-16,698
Prepaid expenses, net deferred income taxes and other current assets	-4,451	-2,487
Accounts payable, accrued expenses and other liabilities	-24,267	-13,293
Net cash provided by operating activities	90,425	78,254
Cash flows from investing activities:
Purchases of property, plant and equipment	-16,752	-13,831
Patent registration costs	-1,679	-1,035
Business acquisitions, net of cash acquired		-5,418
Investments in cost-method investments	-675
Purchases of foreign currency options		-402
(Payments)/Proceeds from exercise of foreign currency options	-2,486	5,703
Net cash used in investing activities	-21,592	-14,983
Cash flows from financing activities:
Proceeds from issuance of common stock, net	6,470	21,667
Excess tax benefit from stock-based compensation arrangements	2,241	3,760
Purchases of treasury stock	-22,822	-8,095
Payment of business combination contingent consideration	-442	-1,641
Proceeds from borrowings	60,000	15,000
Repayment of borrowings	-9	-158
Dividend paid	-35,478	-22,843
Net cash provided by financing activities	9,960	7,690
Effect of exchange rate changes on cash	21,733	10,127
Net increase in cash and cash equivalents	100,526	81,088
Cash and cash equivalents at beginning of period	876,048	809,541
Cash and cash equivalents at end of period	976,574	890,629
Supplemental disclosure of cash flow information:
Income taxes paid	39,612	24,565
Interest paid	1,599	1,363
Fair value of assets acquired, excluding cash		7,770
Liabilities assumed		-2,836
Goodwill on acquisition		13,584
Fair value of contingent consideration		-13,100
Total purchase price, excluding contingent consideration		$5,418

Organization_And_Basis_Of_Pres

Organization And Basis Of Presentation	3 Months Ended
	Sep. 30, 2013
Organization And Basis Of Presentation [Abstract]
Organization And Basis Of Presentation	(1)Organization and Basis of Presentation
	ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group.  Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea.  Our manufacturing operations are located in Australia, Singapore, France, Germany, Malaysia and the United States.  Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, Norway and Sweden.
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements.  In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods.  The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the year ending June 30, 2014.
	The condensed consolidated financial statements for the three months ended September 30, 2013 and 2012 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended June 30, 2013.

Recently_Issued_Accounting_Pro

Recently Issued Accounting Pronouncements	3 Months Ended
	Sep. 30, 2013
Recently Issued Accounting Pronouncements [Abstract]
Recently Issued Accounting Pronouncements
	(2)Recently Issued Accounting Pronouncements
	In June 2011, the FASB issued authoritative guidance with respect to the presentation of other comprehensive income in financial statements.  The main provisions of the standard provide that an entity that reports other comprehensive income has the option to present comprehensive income in either a single statement or in a two-statement approach.  A single statement must present the components of net income and total net income, the components of other comprehensive income and total other comprehensive income, and a total for comprehensive income.  In the two-statement approach, an entity must present the components of net income and total net income in the first statement, followed by a financial statement that presents the components of other comprehensive income, a total for other comprehensive income, and a total for comprehensive income.  The adoption of this standard in fiscal year 2013 affected the presentation of our other comprehensive income but not our financial position or results of operations.

Earnings_Per_Share

Earnings Per Share	3 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]
Earnings Per Share	(3)Earnings Per Share
	Basic earnings per share is computed by dividing the net income available to common stockholders by the weighted average number of shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average number of shares of common stock outstanding and the number of dilutive common stock equivalents such as stock options and restricted stock units.
	Stock options of 209,856 and 591,435 for the three months ended September 30, 2013 and 2012, respectively, were not included in the computation of diluted earnings per share as the effect of exercising these options would have been anti-dilutive.
	Basic and diluted earnings per share for the three months ended September 30, 2013 and 2012 are calculated as follows (in thousands except per share data):
		Three Months Ended September 30,
		2013		2012
	Numerator:
	Net Income, used in calculating diluted earnings per share	$	80,930	$	71,265
	Denominator:
	Basic weighted-average common shares outstanding		142,005		142,651
	Effect of dilutive securities:
	Stock options and restricted stock units		3,451		3,404
	Diluted weighted average shares		145,456		146,055
	Basic earnings per share	$	0.57	$	0.50
	Diluted earnings per share	$	0.56	$	0.49

Inventories

Inventories	3 Months Ended
	Sep. 30, 2013
Inventories [Abstract]
Inventories	(4)Inventories
	Inventories were comprised of the following at September 30, 2013 and June 30, 2013 (in thousands):
		30-Sep-13		30-Jun-13
	Raw materials	$	52,606	$	46,841
	Work in progress		1,832		1,990
	Finished goods		120,917		97,016
	Total inventories	$	175,355	$	145,847

Property_Plant_And_Equipment

Property, Plant And Equipment	3 Months Ended
	Sep. 30, 2013
Property, Plant And Equipment [Abstract]
Property, Plant And Equipment	(5)Property, Plant and Equipment
	Property, plant and equipment were comprised of the following as of September 30, 2013 and June 30, 2013 (in thousands):
		30-Sep-13		30-Jun-13
	Machinery and equipment	$	174,716	$	165,782
	Computer equipment		116,542		109,657
	Furniture and fixtures		41,295		40,706
	Vehicles		3,627		3,282
	Clinical, demonstration and rental equipment		97,723		102,304
	Leasehold improvements		29,537		28,466
	Land		62,001		61,091
	Buildings		263,273		260,857
			788,714		772,145
	Accumulated depreciation and amortization		-371,969		-360,712
	Property, plant and equipment, net	$	416,745	$	411,433

CostMethod_Investments

Cost-Method Investments	3 Months Ended
	Sep. 30, 2013
Cost-Method Investments [Abstract]
Cost-Method Investments	(6)Cost-Method Investments
	The aggregate carrying amount of our cost-method investments at September 30, 2013 and June 30, 2013, was $4.7 million and $4.0 million, respectively, and is included in the non-current balance of other assets on the condensed consolidated balance sheets.
	We periodically evaluate the carrying value of our cost-method investments, when events and circumstances indicate that the carrying amount of an asset may not be recovered.  We estimate the fair value of our cost-method investments to assess whether impairment losses shall be recorded using Level 3 inputs. These investments include our holdings in privately held service and research companies that are not exchange traded and therefore not supported with observable market prices. However, these investments are valued by reference to their net asset values which can be market supported and unobservable inputs including future cash flows.  During the three months ended September 30, 2013 and 2012, we recognized $Nil and $Nil, respectively, of impairment losses related to our cost-method investments.  We have determined that the fair value of our investments exceed their carrying values.
	The following table shows a reconciliation of the changes in our cost-method investments during the three months ended September 30, 2013 and 2012 (in thousands):
		Three Months Ended September 30,
		2013		2012
	Balance at the beginning of the period	$	4,000	$	2,250
	Investments		675		-
	Balance at the end of the period	$	4,675	$	2,250

Goodwill_And_Other_Intangible_

Goodwill And Other Intangible Assets, Net	3 Months Ended
	Sep. 30, 2013
Goodwill And Other Intangible Assets, Net [Abstract]
Goodwill And Other Intangible Assets, Net	(7)Goodwill and Other Intangible Assets, net
	Goodwill
	Changes in the carrying amount of goodwill for the three months ended September 30, 2013, and 2012 were as follows (in thousands):
		Three Months Ended September 30,
		2013		2012
	Balance at the beginning of the period	$	274,829	$	256,209
	Business acquisition		-		13,584
	Foreign currency translation adjustments		8,616		3,487
	Balance at the end of the period	$	283,445	$	273,280
	Other Intangible Assets
	Other intangible assets are comprised of the following as of September 30, 2013,  and June 30, 2013 (in thousands):
		30-Sep-13		June 30, 2013
	Developed/core product technology	$	75,139	$	72,698
	Accumulated amortization		-48,729		-45,492
	Developed/core product technology, net		26,410		27,206
	Trade names		2,742		2,662
	Accumulated amortization		-2,610		-2,491
	Trade names, net		132		171
	Non-compete agreements		2,115		2,068
	Accumulated amortization		-1,408		-1,265
	Non compete agreements, net		707		803
	Customer relationships		22,992		22,291
	Accumulated amortization		-18,387		-17,095
	Customer relationships, net		4,605		5,196
	Patents		63,108		59,962
	Accumulated amortization		-46,289		-43,699
	Patents, net		16,819		16,263
	Total other intangibles, net	$	48,673	$	49,639
	Intangible assets consist of patents, customer relationships, trade names, non-compete agreements and developed/core product technology.  We amortize intangible assets over the estimated useful life of the assets, generally between two and nine years. There are no expected residual values related to these intangible assets.

LongTerm_Debt

Long-Term Debt	3 Months Ended
	Sep. 30, 2013
Long-Term Debt [Abstract]
Long-Term Debt	(8)Long-Term Debt
	Long-term debt at September 30, 2013 and June 30, 2013 consists of the following (in thousands):
		30-Sep-13		June 30, 2013
	Current long-term debt	$	360,018	$	300,017
	Non-current long-term debt		790		769
	Total long-term debt	$	360,808	$	300,786
	Credit Facility
	During the year ended June 30, 2011, we entered into a credit agreement with lenders, including Union Bank, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, HSBC Bank USA, National Association, as Syndication Agent and Union Bank, N.A., HSBC Bank USA, National Association, Commonwealth Bank of Australia and Wells Fargo Bank, N.A. The credit agreement provides a $300 million three-year revolving credit facility, with an uncommitted option to increase the credit facility by an additional $100 million. The credit facility also includes a $10 million sublimit for letters of credit. The credit facility terminates on February 10, 2014, at which time all unpaid principal and interest under the loans must be repaid. The outstanding principal amount due
	under the credit facility will bear interest at a rate equal to, at our option, either (i) LIBOR plus 1.5% to 2.0% (depending on the applicable leverage ratio) or (ii) a base rate, as defined in the credit agreement, plus 0.5% to 1.0% (depending on the applicable leverage ratio). At September 30, 2013, the interest rate that was being charged on the outstanding principal amount was 1.7%. Commitment fees of 0.25% to 0.375% (depending on the applicable leverage ratio) apply on the unused portion of the credit facility. When we executed the credit agreement, we used a portion of the credit facility’s initial funding proceeds to repay the outstanding balance under our previously existing revolving credit facility with Union Bank, N.A., which was then terminated.
	Our obligations under the credit agreement are secured by (a) the corporate stock we hold in our subsidiaries ResMed Corp. and ResMed Motor Technologies Inc. ("ResMed Motor"), and (b) up to 65% of the ownership interests we hold in our subsidiary ResMed EAP Holdings LLC ("ResMed EAP"). Our obligations under the credit agreement are also guaranteed by our subsidiaries ResMed Corp. and ResMed Motor.  The credit agreement contains customary covenants, including certain financial covenants and an obligation that we maintain certain financial ratios, including a maximum ratio of Funded Debt to EBITDA (each as defined in the credit agreement), an interest coverage ratio and a maximum amount of annual capital expenditures. The entire principal amount of the credit facility and any accrued but unpaid interest may be declared immediately due and payable if an event of default occurs. Events of default include failure to make payments when due, a default in the performance of any covenants in the credit agreement or related documents or certain changes of control of us or our subsidiaries ResMed Corp, ResMed Motor, ResMed Limited, ResMed Holdings Ltd/LLC or ResMed EAP.
	On January 25, 2012, we entered into a first amendment to the credit agreement.  The amendment increases, from $300 million to $400 million, the maximum principal amount that can be borrowed on a revolving basis under the credit agreement, subject to customary conditions.
	At September 30, 2013,  there was $360.0 million outstanding under the credit agreement.

Product_Warranties

Product Warranties	3 Months Ended
	Sep. 30, 2013
Product Warranties [Abstract]
Product Warranties	(9)Product Warranties
	Changes in the liability for warranty costs, which is included in accrued expenses in our condensed consolidated balance sheets, for the three months ended September 30, 2013 and 2012 are as follows (in thousands):
		Three Months Ended September 30,
		2013		2012
	Balance at the beginning of the period	$	16,011	$	17,018
	Warranty accruals for the period		2,796		3,251
	Warranty costs incurred for the period		-2,270		-2,478
	Foreign currency translation adjustments		368		23
	Balance at the end of the period	$	16,905	$	17,814

StockBased_Employee_Compensati

Stock-Based Employee Compensation	3 Months Ended
	Sep. 30, 2013
Stock-Based Employee Compensation [Abstract]
Stock-Based Employee Compensation	(10)Stock-Based Employee Compensation
	We measure the compensation expense of all stock-based awards at fair value on the grant date.  We estimate the fair value of stock options and purchase rights granted under the employee stock purchase plan (the “ESPP”) using the Black-Scholes valuation model. The fair value of restricted stock units is equal to the market value of the underlying shares as determined at the grant date less the fair value of dividends that holders are not entitled to, during the vesting period.  We recognize the fair value as compensation expense using the straight-line method over the service period for awards expected to vest.
	We estimate the fair value of stock options granted under our stock option plans and purchase rights granted under the ESPP using the following assumptions:
		Three Months Ended September 30,
		2013		2012
	Stock options:
	Weighted average grant date fair value	$	-	$	8.01
	Weighted average risk-free interest rate		-		0.70%
	Expected option life in years		-		5.29
	Dividend yield		-		2%
	Expected volatility		-		34%
	ESPP purchase rights:
	Weighted average risk-free interest rate		0.08%		0.15%
	Expected option life in years		6 months		6 months
	Dividend yield		1.44%		0%
	Expected volatility		24%		30%

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Sep. 30, 2013
Stockholders' Equity [Abstract]
Stockholders' Equity	(11)Stockholders’ Equity
	Common Stock.    On August 24, 2011, our board of directors approved a new share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of ResMed Inc. common stock.  The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negotiated or block transactions, as market and business conditions warrant.  This program canceled and replaced our previous share repurchase program authorized on May 27, 2009 pursuant to which we had repurchased 10.0 million shares.  These were in addition to the 6.6 million shares repurchased under an earlier program authorized on June 6, 2002.  The new program authorizes us to purchase in addition to the shares we repurchased under our previous programs.  There is no expiration date for this program.  All share repurchases since August 24, 2011 have been executed in accordance with this program.
	During the three months ended September 30, 2013, we repurchased 0.4 million shares at a cost of $21.1 million.  Since the inception of our share repurchase programs and through September 30, 2013, we have repurchased a total of 32.5 million shares at a cost of $1.1 billion.  Shares that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share.  At September 30, 2013,  4.1 million additional shares can be repurchased under the approved share repurchase program.
	Preferred Stock.    In April 1997, the board of directors designated 2,000,000 shares of our $0.01 par value preferred stock as Series A Junior Participating Preferred Stock. No such shares were issued or outstanding at September 30, 2013 and June 30, 2013.
	Stock Options and Restricted Stock Units.    We have granted stock options and restricted stock units to personnel, including officers and directors, in accordance with ResMed Inc. 2009 Incentive Award Plan (the “2009 Plan”).  These options and restricted stock units have expiration dates of seven years from the date of grant and vest over one to four years. We have granted the options with an exercise price equal to the market value as determined at the date of grant.
	The maximum number of shares of our common stock authorized for issuance under the 2009 Plan is 35.5 million shares. The number of securities remaining available for future issuance under the 2009 Plan at September 30, 2013 is 10.2 million.  The number of shares of our common stock available for issuance under the 2009 Plan will be reduced by (i) three  (3.0) shares for each one share of common stock delivered in settlement of any “full-value award,” which is any award other than a stock option, stock appreciation right or other award for which the holder pays the intrinsic value and (ii) one share for each share of common stock delivered in settlement of all other awards.  The maximum number of shares, which may be subject to awards granted under the 2009 Plan to any individual during any calendar year, may not exceed 3 million shares of our common stock (except in a participant’s initial year of hiring up to 4.5 million shares of our common stock may be granted).
	At September 30, 2013, there was $66.4 million in unrecognized compensation costs related to unvested stock-based compensation arrangements. This is expected to be recognized over a weighted average period of 2.3 years.  The aggregate intrinsic value of the stock-based compensation arrangements outstanding and exercisable at September 30, 2013 was $314.1 million and $146.2 million, respectively.  The aggregate intrinsic value of the options exercised during the three months ended September 30, 2013 and 2012, was $11.5 million and $21.7 million, respectively.
	The following table summarizes option activity during the three months ended September 30, 2013:
			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years
	Outstanding at beginning of period	6,316,136	$	22.68	3.1
	Granted	-		-
	Exercised	-372,828		18.70
	Forfeited	-10,250		30.78
	Outstanding at end of period	5,933,058	$	22.92	2.9
	Exercise price range of granted options	-
	Options exercisable at end of period	4,378,304	$	19.43
	The following table summarizes the activity of restricted stock units during the three months ended September 30, 2013:
			Weighted Average Grant-Date Fair Value		Weighted Average Remaining Contractual Term in Years
	Outstanding at beginning of period	2,633,407	$	33.25	1.4
	Granted	1,500		43.31
	Vested	-31,070		30.69
	Forfeited	-17,050		30.55
	Outstanding at end of period	2,586,787	$	33.30	1.2
	Employee Stock Purchase Plan (the “ESPP”).  Under the ESPP, we offer participants the right to purchase shares of our common stock at a discount during successive offering periods. Each offering period under the ESPP will be for a period of time determined by the board of directors’ compensation committee of no less than 3 months and no more than 27 months. The purchase price for our common stock under the ESPP will be the lower of 85% of the fair market value of our common stock on the date of grant or 85% of the fair market value of our common stock on the date of purchase. An individual participant cannot subscribe for more than $25,000 in common stock during any calendar year.  At September 30, 2013, the number of shares remaining available for future issuance under the ESPP is 2.1 million shares.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Sep. 30, 2013
Fair Value Measurements [Abstract]
Fair Value Measurements
	(12)Fair Value Measurements
	In determining the fair value measurements of our financial assets and liabilities, we consider the principal and most advantageous market in which we transact and consider assumptions that market participants would use when pricing the financial asset or liability.  We maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
	The hierarchies of inputs are as follows:
	·	Level 1:Input prices quoted in an active market for identical financial assets or liabilities;
	·	Level 2:Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data; and
	·	Level 3:Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable nor supported by an active market.
	The following table summarizes our financial assets and liabilities, as at September 30, 2013 and June 30, 2013, using the valuation input hierarchy (in thousands):
			Level 1		Level 2		Level 3		Total
	Balances at September 30, 2013
	Foreign currency hedging instruments, net	$	-	$	-7,882	$	-	$	-7,882
	Business acquisition contingent consideration	$	-	$	-	$	-7,423	$	-7,423
	Balances at June 30, 2013
	Foreign currency hedging instruments, net	$	-	$	-7,000	$	-	$	-7,000
	Business acquisition contingent consideration	$	-	$	-	$	-7,779	$	-7,779
	We determine the fair value of our financial assets and liabilities as follows:
	Foreign currency hedging instruments – These financial instruments are valued using third-party valuation models based on market observable inputs, including interest rate curves, on-market spot currency prices, volatilities and credit risk.
	Contingent consideration – These liabilities include the fair value estimates of additional future payments that may be required for some of our previous business acquisitions based on the achievement of certain performance milestones.  Each potential future payment is valued using the estimated probability of achieving each milestone, which is then discounted to present value.
	The following is a reconciliation of changes in the fair value of contingent consideration during three months ended September 30, 2013 (in thousands):
		Three Months Ended September 30, 2013
	Balance at the beginning of the period	$	-7,779
	Payments		442
	Foreign currency translation adjustments		-86
	Balance at the end of the period	$	-7,423
	We did not have any significant non-financial assets or liabilities measured at fair value on September 30, 2013 or June 30, 2013.

Legal_Actions_And_Contingencie

Legal Actions And Contingencies	3 Months Ended
	Sep. 30, 2013
Legal Actions And Contingencies [Abstract]
Legal Actions And Contingencies	(13)Legal Actions and Contingencies
	Litigation
	In the normal course of business, we are subject to routine litigation incidental to our business.  While the results of this litigation cannot be predicted with certainty, we believe that their final outcome will not, individually or in aggregate, have a material adverse effect on our consolidated financial statements taken as a whole.
	In March 2013, we filed parallel legal actions in the International Trade Commission, or ITC, and in U.S. district court against Taiwanese manufacturer APEX and its U.S. distributor to stop the infringement of several ResMed patents.  In July 2013, the ITC entered a consent decree against the U.S. distributor, ordering that it not import or sell after import certain products we accused of infringing our patents.  In August 2013, the ITC entered a consent decree against APEX, ordering that it not import or sell after import products that infringe the claims of the patents that ResMed asserted against APEX.  Thereafter, APEX initiated inter partes review proceedings in the U.S. Patent and Trademark Office, or PTO, challenging the validity of most of the claims asserted against APEX in the ITC.  The U.S. district court has stayed the litigation against APEX and the U.S. distributor pending the resolution of the inter partes review by the PTO.  APEX has advised the ITC that is has redesigned the accused products and requested that the ITC determine that those products are not subject to the consent decree.  Therefore the matter is ongoing as to APEX.   However, we do not expect the outcome of this matter to have a material adverse effect on our consolidated financial statements when taken as a whole.
	In June 2013, we filed a lawsuit in U.S. district court against Chinese manufacturer BMC Medical Co., Ltd and its U.S. affiliates to stop the infringement of several ResMed patents.  In July 2013, we amended the district court lawsuit, and filed a parallel proceeding in the ITC.  The ITC initiated an investigation of BMC’s alleged infringement in August 2013, and that matter is proceeding in the normal course.  The district court lawsuit has been stayed by the court pending the conclusion of the ITC proceeding.  The BMC matter is ongoing.  However, we do not expect the outcome of this matter to have a material adverse effect on our consolidated financial statements when taken as a whole.

Derivative_Instruments_And_Hed

Derivative Instruments And Hedging Activities	3 Months Ended
	Sep. 30, 2013
Derivative Instruments And Hedging Activities [Abstract]
Derivative Instruments And Hedging Activities	(14)Derivative Instruments and Hedging Activities
	We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have significant foreign currency exposure through both our Australian and Singaporean manufacturing activities, and international sales operations.  We have established a foreign currency hedging program using purchased currency options and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows.  The terms of such foreign currency hedging contracts generally do not exceed three years.  The goal of this hedging program is to economically manage the financial impact of foreign currency exposures denominated mainly in Euros, Australian and Singapore dollars.  Under this program, increases or decreases in our foreign currency denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments.
	We do not designate these foreign currency contracts as hedges.  We have determined our hedge program to be a non-effective hedge as defined under the FASB issued authoritative guidance.  All movements in the fair value of the foreign currency instruments are recorded within other income, net in our condensed consolidated statements of income.  We do not enter into financial instruments for trading or speculative purposes.
	We held foreign currency instruments with notional amounts totaling $391.4 million and $462.1 million at September 30, 2013 and June 30, 2013, respectively, to hedge foreign currency fluctuations.  These contracts mature at various dates prior to September 30, 2016.
	The following table summarizes the amount and location of our derivative financial instruments as of September 30, 2013 and June 30, 2013 (in thousands):
		30-Sep-13		30-Jun-13		Balance Sheet Caption
	Foreign currency hedging instruments	$	1,175	$	1,350		Other assets - current
	Foreign currency hedging instruments		213		657		Other assets - non current
	Foreign currency hedging instruments		-9,270		-9,007		Accrued expenses
		$	-7,882	$	-7,000
	The following table summarizes the amount and location of gains (losses) associated with our derivative financial instruments for the three months ended September 30, 2013 and September 30, 2012, respectively (in thousands):
		Gain /(Loss) Recognized				Income Statement Caption
		Three Months Ended September 30,
		2013		2012
	Foreign currency hedging instruments	$	-3,156	$	1,083		Other, net
	Other foreign-currency-denominated transactions		1,741		656		Other, net
		$	-1,415	$	1,739
	We are exposed to credit-related losses in the event of non-performance by counter parties to financial instruments.  We minimize counterparty credit risk by entering into derivative transactions with major financial institutions and we do not expect material losses as a result of default by our counterparties.

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	3 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]
Schedule Of Basic And Diluted Earnings Per Share
		Three Months Ended September 30,
		2013		2012
	Numerator:
	Net Income, used in calculating diluted earnings per share	$	80,930	$	71,265
	Denominator:
	Basic weighted-average common shares outstanding		142,005		142,651
	Effect of dilutive securities:
	Stock options and restricted stock units		3,451		3,404
	Diluted weighted average shares		145,456		146,055
	Basic earnings per share	$	0.57	$	0.50
	Diluted earnings per share	$	0.56	$	0.49

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Sep. 30, 2013
Inventories [Abstract]
Schedule Of Inventories
		30-Sep-13		30-Jun-13
	Raw materials	$	52,606	$	46,841
	Work in progress		1,832		1,990
	Finished goods		120,917		97,016
	Total inventories	$	175,355	$	145,847

Property_Plant_And_Equipment_T

Property, Plant And Equipment (Tables)	3 Months Ended
	Sep. 30, 2013
Property, Plant And Equipment [Abstract]
Components Of Property, Plant And Equipment
		30-Sep-13		30-Jun-13
	Machinery and equipment	$	174,716	$	165,782
	Computer equipment		116,542		109,657
	Furniture and fixtures		41,295		40,706
	Vehicles		3,627		3,282
	Clinical, demonstration and rental equipment		97,723		102,304
	Leasehold improvements		29,537		28,466
	Land		62,001		61,091
	Buildings		263,273		260,857
			788,714		772,145
	Accumulated depreciation and amortization		-371,969		-360,712
	Property, plant and equipment, net	$	416,745	$	411,433

CostMethod_Investments_Tables

Cost-Method Investments (Tables)	3 Months Ended
	Sep. 30, 2013
Cost-Method Investments [Abstract]
Schedule Of Reconciliation Of Changes In Cost-Method Investments
		Three Months Ended September 30,
		2013		2012
	Balance at the beginning of the period	$	4,000	$	2,250
	Investments		675		-
	Balance at the end of the period	$	4,675	$	2,250

Goodwill_And_Other_Intangible_1

Goodwill And Other Intangible Assets, Net (Tables)	3 Months Ended
	Sep. 30, 2013
Goodwill And Other Intangible Assets, Net [Abstract]
Schedule Of Changes In Carrying Amount Of Goodwill
		Three Months Ended September 30,
		2013		2012
	Balance at the beginning of the period	$	274,829	$	256,209
	Business acquisition		-		13,584
	Foreign currency translation adjustments		8,616		3,487
	Balance at the end of the period	$	283,445	$	273,280
Schedule Of Other Intangible Assets
		30-Sep-13		June 30, 2013
	Developed/core product technology	$	75,139	$	72,698
	Accumulated amortization		-48,729		-45,492
	Developed/core product technology, net		26,410		27,206
	Trade names		2,742		2,662
	Accumulated amortization		-2,610		-2,491
	Trade names, net		132		171
	Non-compete agreements		2,115		2,068
	Accumulated amortization		-1,408		-1,265
	Non compete agreements, net		707		803
	Customer relationships		22,992		22,291
	Accumulated amortization		-18,387		-17,095
	Customer relationships, net		4,605		5,196
	Patents		63,108		59,962
	Accumulated amortization		-46,289		-43,699
	Patents, net		16,819		16,263
	Total other intangibles, net	$	48,673	$	49,639

LongTerm_Debt_Tables

Long-Term Debt (Tables)	3 Months Ended
	Sep. 30, 2013
Long-Term Debt [Abstract]
Schedule Of Long-Term Debt
		30-Sep-13		June 30, 2013
	Current long-term debt	$	360,018	$	300,017
	Non-current long-term debt		790		769
	Total long-term debt	$	360,808	$	300,786

Product_Warranties_Tables

Product Warranties (Tables)	3 Months Ended
	Sep. 30, 2013
Product Warranties [Abstract]
Schedule Of Changes In Liability For Warranty Costs
		Three Months Ended September 30,
		2013		2012
	Balance at the beginning of the period	$	16,011	$	17,018
	Warranty accruals for the period		2,796		3,251
	Warranty costs incurred for the period		-2,270		-2,478
	Foreign currency translation adjustments		368		23
	Balance at the end of the period	$	16,905	$	17,814

StockBased_Employee_Compensati1

Stock-Based Employee Compensation (Tables)	3 Months Ended
	Sep. 30, 2013
Stock-Based Employee Compensation [Abstract]
Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted
		Three Months Ended September 30,
		2013		2012
	Stock options:
	Weighted average grant date fair value	$	-	$	8.01
	Weighted average risk-free interest rate		-		0.70%
	Expected option life in years		-		5.29
	Dividend yield		-		2%
	Expected volatility		-		34%
	ESPP purchase rights:
	Weighted average risk-free interest rate		0.08%		0.15%
	Expected option life in years		6 months		6 months
	Dividend yield		1.44%		0%
	Expected volatility		24%		30%

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	3 Months Ended
	Sep. 30, 2013
Stockholders' Equity [Abstract]
Schedule Of Option Activity
			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years
	Outstanding at beginning of period	6,316,136	$	22.68	3.1
	Granted	-		-
	Exercised	-372,828		18.70
	Forfeited	-10,250		30.78
	Outstanding at end of period	5,933,058	$	22.92	2.9
	Exercise price range of granted options	-
	Options exercisable at end of period	4,378,304	$	19.43
Schedule Of Activity Of Restricted Stock Units
			Weighted Average Grant-Date Fair Value		Weighted Average Remaining Contractual Term in Years
	Outstanding at beginning of period	2,633,407	$	33.25	1.4
	Granted	1,500		43.31
	Vested	-31,070		30.69
	Forfeited	-17,050		30.55
	Outstanding at end of period	2,586,787	$	33.30	1.2

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Sep. 30, 2013
Fair Value Measurements [Abstract]
Summary Of Financial Assets And Liabilities
			Level 1		Level 2		Level 3		Total
	Balances at September 30, 2013
	Foreign currency hedging instruments, net	$	-	$	-7,882	$	-	$	-7,882
	Business acquisition contingent consideration	$	-	$	-	$	-7,423	$	-7,423
	Balances at June 30, 2013
	Foreign currency hedging instruments, net	$	-	$	-7,000	$	-	$	-7,000
	Business acquisition contingent consideration	$	-	$	-	$	-7,779	$	-7,779
Reconciliation For Fair Value Measurements Using Significant Unobservable Inputs
		Three Months Ended September 30, 2013
	Balance at the beginning of the period	$	-7,779
	Payments		442
	Foreign currency translation adjustments		-86
	Balance at the end of the period	$	-7,423

Derivative_Instruments_And_Hed1

Derivative Instruments And Hedging Activities (Tables)	3 Months Ended
	Sep. 30, 2013
Derivative Instruments And Hedging Activities [Abstract]
Summary Of Amount And Location Of Derivative Financial Instruments
		30-Sep-13		30-Jun-13		Balance Sheet Caption
	Foreign currency hedging instruments	$	1,175	$	1,350		Other assets - current
	Foreign currency hedging instruments		213		657		Other assets - non current
	Foreign currency hedging instruments		-9,270		-9,007		Accrued expenses
		$	-7,882	$	-7,000
Summary Of Gains (Losses) Associated With Derivative Financial Instruments
		Gain /(Loss) Recognized				Income Statement Caption
		Three Months Ended September 30,
		2013		2012
	Foreign currency hedging instruments	$	-3,156	$	1,083		Other, net
	Other foreign-currency-denominated transactions		1,741		656		Other, net
		$	-1,415	$	1,739

Earnings_Per_Share_Narrative_D

Earnings Per Share (Narrative) (Details)	3 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Earnings Per Share [Abstract]
Stock options not included in the computation of diluted earnings per share	209,856	591,435

Earnings_Per_Share_Schedule_Of

Earnings Per Share (Schedule Of Basic And Diluted Earnings Per Share) (Details) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Earnings Per Share [Abstract]
Net Income, used in calculating diluted earnings per share	$80,930	$71,265
Basic weighted-average common shares outstanding	142,005	142,651
Effect of dilutive securities, stock options and restricted stock units	3,451	3,404
Diluted weighted average shares	145,456	146,055
Basic earnings per share	$0.57	$0.50
Diluted earnings per share	$0.56	$0.49

Inventories_Schedule_Of_Invent

Inventories (Schedule Of Inventories) (Details) (USD $)	Sep. 30, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Inventories [Abstract]
Raw materials	$52,606	$46,841
Work in progress	1,832	1,990
Finished goods	120,917	97,016
Total inventories	$175,355	$145,847

Property_Plant_And_Equipment_D

Property, Plant And Equipment (Details) (USD $)	Sep. 30, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$788,714	$772,145
Accumulated depreciation and amortization	-371,969	-360,712
Property, plant and equipment, net	416,745	411,433
Machinery And Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	174,716	165,782
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	116,542	109,657
Furniture And Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	41,295	40,706
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	3,627	3,282
Clinical, Demonstration And Rental Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	97,723	102,304
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	29,537	28,466
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	62,001	61,091
Buildings [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$263,273	$260,857

CostMethod_Investments_Narrati

Cost-Method Investments (Narrative) (Details) (USD $)	Sep. 30, 2013	Jun. 30, 2013	Sep. 30, 2012	Jun. 30, 2012
In Thousands, unless otherwise specified
Cost-Method Investments [Abstract]
Aggregate carrying amount of cost-method investments	$4,675	$4,000	$2,250	$2,250

CostMethod_Investments_Schedul

Cost-Method Investments (Schedule Of Reconciliation Of Changes In Cost-Method Investments) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Jun. 30, 2012
Cost-Method Investments [Abstract]
Balance at the beginning of the period	$4,000	$2,250	$2,250
Investments	675
Balance at the end of the period	$4,675	$2,250	$2,250

Goodwill_And_Other_Intangible_2

Goodwill And Other Intangible Assets, Net (Schedule Of Changes In Carrying Amount Of Goodwill) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Goodwill And Other Intangible Assets, Net [Abstract]
Balance at the beginning of the period	$274,829	$256,209
Business acquisition		13,584
Foreign currency translation adjustments	8,616	3,487
Balance at the end of the period	$283,445	$273,280

Goodwill_And_Other_Intangible_3

Goodwill And Other Intangible Assets, Net (Schedule Of Other Intangible Assets) (Details) (USD $)	Sep. 30, 2013	Jun. 30, 2013	Sep. 30, 2013	Jun. 30, 2013	Sep. 30, 2013	Jun. 30, 2013	Sep. 30, 2013	Jun. 30, 2013	Sep. 30, 2013	Jun. 30, 2013	Sep. 30, 2013	Jun. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
In Thousands, unless otherwise specified			Developed/Core Product Technology [Member]	Developed/Core Product Technology [Member]	Trade Names [Member]	Trade Names [Member]	Non Compete Agreements [Member]	Non Compete Agreements [Member]	Customer Relationships [Member]	Customer Relationships [Member]	Patents [Member]	Patents [Member]	Minimum [Member]	Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross			$75,139	$72,698	$2,742	$2,662	$2,115	$2,068	$22,992	$22,291	$63,108	$59,962
Accumulated amortization			-48,729	-45,492	-2,610	-2,491	-1,408	-1,265	-18,387	-17,095	-46,289	-43,699
Total other intangibles, net	$48,673	$49,639	$26,410	$27,206	$132	$171	$707	$803	$4,605	$5,196	$16,819	$16,263
Intangible assets, estimated useful life													2 years	9 years

LongTerm_Debt_Narrative_Detail

Long-Term Debt (Narrative) (Details) (USD $)	3 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Jun. 30, 2011
Debt Instrument [Line Items]
Revolving credit facility, maximum borrowing capacity	$400	$300
Credit facility term, years		3 years
Additional option to increase credit facility borrowings		100
Credit facility termination date	10-Feb-14
Ownership interests held by the entity, maximum	65.00%
Interest rate on outstanding principal amount	1.70%
Amount outstanding under credit facility	360
Letters Of Credit [Member]
Debt Instrument [Line Items]
Revolving credit facility, maximum borrowing capacity		$10
Minimum [Member]
Debt Instrument [Line Items]
Commitment fees percentage rate on unused portion of credit facility	0.25%
Minimum [Member] | LIBOR Plus [Member]
Debt Instrument [Line Items]
Credit facility interest rate equal to reference rate plus	1.50%
Minimum [Member] | Base Rate Plus [Member]
Debt Instrument [Line Items]
Credit facility interest rate equal to reference rate plus	0.50%
Maximum [Member]
Debt Instrument [Line Items]
Commitment fees percentage rate on unused portion of credit facility	0.38%
Maximum [Member] | LIBOR Plus [Member]
Debt Instrument [Line Items]
Credit facility interest rate equal to reference rate plus	2.00%
Maximum [Member] | Base Rate Plus [Member]
Debt Instrument [Line Items]
Credit facility interest rate equal to reference rate plus	1.00%

LongTerm_Debt_Schedule_Of_Long

Long-Term Debt (Schedule Of Long-Term Debt) (Details) (USD $)	Sep. 30, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Long-Term Debt [Abstract]
Current long-term debt	$360,018	$300,017
Non-current long-term debt	790	769
Total long-term debt	$360,808	$300,786

Product_Warranties_Details

Product Warranties (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Product Warranties [Abstract]
Balance at the beginning of the period	$16,011	$17,018
Warranty accruals for the period	2,796	3,251
Warranty costs incurred for the period	-2,270	-2,478
Foreign currency translation adjustments	368	23
Balance at the end of the period	$16,905	$17,814

StockBased_Employee_Compensati2

Stock-Based Employee Compensation (Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted) (Details) (USD $)	3 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value		8.01
Weighted average risk-free interest rate		0.70%
Expected option life in years		5 years 3 months 15 days
Dividend yield		2.00%
Expected volatility		34.00%
ESPP Purchase Rights [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average risk-free interest rate	0.08%	0.15%
Expected option life in years	6 months	6 months
Dividend yield	1.44%	0.00%
Expected volatility	24.00%	30.00%

Stockholders_Equity_Narrative_

Stockholders' Equity (Narrative) (Details) (USD $)	3 Months Ended		136 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Jun. 30, 2013	Aug. 24, 2011	27-May-09	Jun. 06, 2002	Apr. 30, 1997
Stockholders' Equity [Line Items]
Shares authorized to be repurchased under repurchase program					20,000,000	10,000,000	6,600,000
Common shares repurchased	400,000		32,500,000
Cost of common shares repurchased	$21,100,000		$1,100,000,000
Additional shares that can be repurchased under the approved share repurchase program	4,100,000		4,100,000
Treasury stock, shares held	32,457,708		32,457,708	32,026,013
Treasury stock, at cost	1,104,906,000		1,104,906,000	1,083,845,000
Preferred stock, shares authorized	2,000,000		2,000,000	2,000,000				2,000,000
Preferred stock at par value	$0.01		$0.01	$0.01				$0.01
Stock option and restricted stock units expiration period	7 years
Reduction in the number of shares of common stock available for issuance	3		3
Common stock authorized for issuance	35,500,000		35,500,000
Number of securities remaining available for future issuance	10,200,000		10,200,000
Maximum number of shares subject to awards granted	3,000,000		3,000,000
Number of common stock shares granted in participant's initial year of hiring	4,500,000		4,500,000
Unrecognized compensation costs related to unvested stock-based compensation arrangements	66,400,000		66,400,000
Expected weighted average period of unrecognized compensation costs related to unvested stock-based compensation arrangements	2 years 3 months 18 days
Aggregate intrinsic value of the stock-based compensation arrangements outstanding	314,100,000		314,100,000
Aggregate intrinsic value of the stock-based compensation arrangements exercisable	146,200,000		146,200,000
Aggregate intrinsic value of the options exercised	11,500,000	21,700,000
Employee Stock Purchase Plan [Member]
Stockholders' Equity [Line Items]
Number of securities remaining available for future issuance	2,100,000		2,100,000
Percentage of purchase price of common stock lower than the fair market value of common stock on the date of grant	85.00%
Percentage of purchase price of common stock lower than the fair market value of common stock on the date of purchase	85.00%
Minimum [Member]
Stockholders' Equity [Line Items]
Stock options and restricted stock units vesting period	1 year
Minimum [Member] | Employee Stock Purchase Plan [Member]
Stockholders' Equity [Line Items]
Employee stock purchase program offering period	3 months
Maximum [Member]
Stockholders' Equity [Line Items]
Stock options and restricted stock units vesting period	4 years
Maximum [Member] | Employee Stock Purchase Plan [Member]
Stockholders' Equity [Line Items]
Employee stock purchase program offering period	27 months
Common stock shares subscribed	$25,000		$25,000

Stockholders_Equity_Schedule_O

Stockholders' Equity (Schedule Of Option Activity) (Details) (USD $)	3 Months Ended	12 Months Ended
	Sep. 30, 2013	Jun. 30, 2013
Stockholders' Equity [Abstract]
Options, Outstanding at beginning of period	6,316,136
Options, Exercised	-372,828
Options, Forfeited	-10,250
Options, Outstanding at end of period	5,933,058	6,316,136
Options exercisable at end of period	4,378,304
Weighted Average Exercise Price, Outstanding at beginning of period	$22.68
Weighted Average Exercise Price, Exercised	$18.70
Weighted Average Exercise Price, Forfeited	$30.78
Weighted Average Exercise Price, Outstanding at end of period	$22.92	$22.68
Weighted Average Exercise Price, Options exercisable at end of period	$19.43
Weighted Average Remaining Term to Vest in Years, Outstanding	2 years 10 months 24 days	3 years 1 month 6 days

Stockholders_Equity_Schedule_O1

Stockholders' Equity (Schedule Of Activity Of Restricted Stock Units) (Details) (Restricted Stock Units (RSUs) [Member], USD $)	3 Months Ended	12 Months Ended
	Sep. 30, 2013	Jun. 30, 2013
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted Stock Units, Outstanding at beginning of period	2,633,407
Restricted Stock Units, Granted	1,500
Restricted Stock Units, Vested	-31,070
Restricted Stock Units, Forfeited	-17,050
Restricted Stock Units, Outstanding at end of period	2,586,787	2,633,407
Weighted Average Grant-Date Fair Value, Outstanding at beginning of period	$33.25
Weighted Average Grant-Date Fair Value, Granted	$43.31
Weighted Average Grant-Date Fair Value, Vested	$30.69
Weighted Average Grant-Date Fair Value, Forfeited	$30.55
Weighted Average Grant-Date Fair Value, Outstanding at end of period	$33.30	$33.25
Weighted Average Remaining Contractual Term in Years, Outstanding	1 year 2 months 12 days	1 year 4 months 24 days

Fair_Value_Measurements_Summar

Fair Value Measurements (Summary Of Financial Assets And Liabilities) (Details) (USD $)	Sep. 30, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency hedging instruments, net	($7,882)	($7,000)
Business acquisition contingent consideration	-7,423	-7,779
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency hedging instruments, net
Business acquisition contingent consideration
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency hedging instruments, net	-7,882	-7,000
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business acquisition contingent consideration	($7,423)	($7,779)

Fair_Value_Measurements_Reconc

Fair Value Measurements (Reconciliation For Fair Value Measurements Using Significant Unobservable Inputs) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Fair Value Measurements [Abstract]
Balance at the beginning of the period	($7,779)
Payments	442
Foreign currency translation adjustments	-86
Balance at the end of the period	($7,423)

Derivative_Instruments_And_Hed2

Derivative Instruments And Hedging Activities (Narrative) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Jun. 30, 2013
Derivative Instruments And Hedging Activities [Abstract]
Terms of foreign currency hedging contracts, maximum	3 years
Notional amount of foreign currency hedging contracts held	$391.40	$462.10

Derivative_Instruments_And_Hed3

Derivative Instruments And Hedging Activities (Summary Of Amount And Location Of Derivative Financial Instruments) (Details) (Foreign Currency Contracts [Member], USD $)	Sep. 30, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Derivatives, Fair Value [Line Items]
Fair Value - Assets (Liabilities)	($7,882)	($7,000)
Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Fair Value - Assets	1,175	1,350
Other Noncurrent Assets [Member]
Derivatives, Fair Value [Line Items]
Fair Value - Assets	213	657
Accrued Expenses [Member]
Derivatives, Fair Value [Line Items]
Fair Value - Liabilities	($9,270)	($9,007)

Derivative_Instruments_And_Hed4

Derivative Instruments And Hedging Activities (Summary Of Gains (Losses) Associated With Derivative Financial Instruments) (Details) (Derivatives Not Designated As Hedging Instruments [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) Recognized in Income	($1,415)	$1,739
Foreign Currency Contracts [Member] | Other, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Foreign currency-hedging instruments	-3,156	1,083
Other Foreign-currency-denominated Transactions [Member] | Other, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other foreign-currency-denominated transactions	$1,741	$656